SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Aurobindo Pharma informs about transcript of earnings call

25 Feb 2021 Evaluate

With reference to its letter dated February 9, 2021 wherein the company had intimated the schedule of Investors/ Analysts call on February 11, 2021. Aurobindo Pharma has informed that it has enclosed the Transcript of the analyst / investor call on the Un-audited Financial Results of the Company for the third quarter and nine months period ended December 31, 2020 and the same is being uploaded on the website of the Company and is available in the following web link: https://www.aurobindo.com/investors/results-reports-presentations/conference-call-transcripts/.

The above information is a part of company’s filings submitted to BSE.

Aurobindo Pharma Share Price

1428.20 52.40 (3.81%)
05-May-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1820.75
Dr. Reddys Lab 1270.95
Cipla 1333.55
Zydus Lifesciences 911.85
Lupin 2343.40
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×